CD274 and non-small cell lung carcinoma: The PD-1 inhibitor includes Nivolumab, Pembrolizumab, Cemiplimab, Sintilimab, Toripalimab, Camrelizumab, Tislelizumab, etc. PD-L1 inhibitor includes Durvalumab, Atezolizumab, etc. There are 15 PD-1/PD-L1 inhibitors for NSCLC in clinical trials registered in clinicaltrials.gov until 15 January 2022 (Table 1).